This page shows the latest pacritinib news and features for those working in and with pharma, biotech and healthcare.
Thankfully for CTI, it’s been making progress on main pipeline candidate pacritinib , an orally-active kinase inhibitor that targets JAK2, FLT3, IRAK1 and CSF1R and is in phase III testing ... Pacritinib has had its own share of problems, however,
Myelofibrosis candidate pacritinib aiming for accelerated approval. Baxalta and CTI Biopharma have completed their rolling regulatory submission for their myelofibrosis candidate pacritinib in the US, and are aiming for accelerated approval.
Baxter licensed rights to pacritinib from CTI in 2013 in a deal valued at up to $272m deal. ... year. The trial will also compare pacritinib to best available therapy, but in this case that will include JAK2 inhibitors.
pacritinib. Sanofi was forced to discontinue development of its fedratinib (SAR302503) candidate after cases of a rare form of encephalopathy were seen in late-stage trials.
Specifically, the company's chief executive James Bianco maintains that pacritinib is less prone to causing reductions in blood platelet counts, which can limit treatment. ... he added, noting that additional data on pacritinib will be presented at the
Therapeutics/Baxter's pacritinib.
More from news
Approximately 3 fully matching, plus 3 partially matching documents found.
Recent deals: acquired Chatham Therapeutics [$70m]; collaboration Coherus Biosciences, divested vaccines to Pfizer [$625m], global licence Cell Therapeutics for pacritinib.
232. Cell Therapeutics / Baxter. Licence. JAK2/FLT3 inhibitor pacritinib for solid tumours, joint marketing in US includes an equity purchase.
Cell Therapeutics' experimental JAK2/FLT3 inhibitor, pacritinib. ... The Sanofi decision was taken following reported cases consistent with Wernicke's encephalopathy in patients participating in the clinical trials. Pacritinib, an oral therapy, is
More from intelligence
Approximately 0 fully matching, plus 3 partially matching documents found.
up to your ears in it? some pressure is helpful but too much of the wrong sort quickly takes its...